Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | NKTR-255 in R/R MM and NHL

Nina Shah • 7 Dec 2019
ASH 2019
Lymphoma Multiple Myeloma Non-Hodgkin Lymphoma Antibodies Daratumumab NKTR-255

Nina Shah, MD, University of California-San Francisco, San Francisco, CA, outlines a phase I, dose escalation and expansion study (NCT04136756) of NKTR-255, a polymer-conjugated IL-15, as a single agent in relapsed/refractory multiple myeloma (MM) and non-Hodgkin lymphoma (NHL), plus in combination with daratumumab as a salvage regimen for MM. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Nina Shah

19:39
T-Cell Engagers: targets, challenges and opportunity
Hermann Einsele et al. • 27 Mar 2022
1:28
NKTR-255 in multiple myeloma and NHL
Nina Shah • 10 Dec 2021
2:15
Reporting patient experiences during the KarMMa trial
Nina Shah • 10 Dec 2021
2:06
Subanalysis of the KarMMa Trial: Predicting complete response to CAR-T in multiple myeloma
Nina Shah • 10 Dec 2021

Related Videos

History and upcoming projects of the MMRF
Hearn Jay Cho et al. • 3 May 2024
Novel targets & agents in myeloma
Faith Davies et al. • 3 May 2024
Session highlights: sequencing CAR-T cells & bispecifics and managing toxicities
Faith Davies et al. • 3 May 2024
Clinical trial updates in myeloma: managing bone disease, the use of isatuximab, belantamab mafodotin & more
Ola Landgren et al. • 3 May 2024
The content of VJHemOnc is intended for healthcare professionals